ArticleAnnals of translational medicine2020
Cyclic helix B peptide ameliorates renal tubulointerstitial fibrosis induced by unilateral ureter obstruction via inhibiting NLRP3 pathway.
Article in Annals of translational medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 17 citations in OpenAlex.
- Therapy Targeted to the NLRP3 Inflammasome in Chronic Kidney Disease.Kidney diseases (Basel, Switzerland) · 2024Review
- Emergent Peptides of the Antifibrotic Arsenal: Taking Aim at Myofibroblast Promoting Pathways.Biomolecules · 2023Review
- Novel insights into NOD-like receptors in renal diseases.Acta pharmacologica Sinica · 2022Review
- Snai1-induced partial epithelial-mesenchymal transition orchestrates p53-p21-mediated G2/M arrest in the progression of renal fibrosis via NF-κB-mediated inflammation.Cell death & disease · 2021Article
- Cyclic Helix B Peptide Prolongs Skin Allograft SurvivalFrontiers in immunology · 2021Article
- Long-Term Protection of CHBP Against Combinational Renal Injury Induced by Both Ischemia-Reperfusion and Cyclosporine A in Mice.Frontiers in immunology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRenal fibrosis is the inevitable outcome of all progressive chronic kidney diseases (CKD) and leads to a gradual loss of renal function. We previously reported cyclic helix B peptide (CHBP), a novel synthesized peptide derived from erythropoietin, had shown effective renoprotection. In this study, we investigated the anti-fibrotic and renoprotective effect of CHBP in a murine renal tubulointerstitial fibrosis model induced by unilateral ureter obstruction (UUO).
methodsMice were subjected to the UUO model and CHBP was given intraperitoneally. To assess the therapeutic effects of CHBP, pathological injury, deposition of extracellular matrix (ECM) and the progression of epithelial-mesenchymal transition (EMT) were examined
resultsCHBP significantly ameliorated renal tubulointerstitial injury and fibrosis in terms of ECM deposition. The EMT process was also alleviated after CHBP treatment. Similar therapeutic effects of CHBP were also observed
conclusionsOur results suggest that CHBP could effectively protect the kidney from renal tubulointerstitial fibrosis in the UUO model via counteracting the NLRP3/caspase-1/IL-1β pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.